Deleted Journal,
Год журнала:
2024,
Номер
19(2), С. 44 - 59
Опубликована: Авг. 9, 2024
The
poly
(ADP-ribose)
polymerase
(PARP)
family
of
enzymes
involves
and
regulates
various
cellular
processes
essential
functions,
such
as
apoptosis,
transcription
process,
DNA
repair.
PARPs
(PARP-1,
PARP-2,
PARP-3)
are
a
branch
familiar
proteins
that
play
crucial
role
in
repairing
damage
human
gene
involved
different
cancers
regulate
the
base
excision
repair
(BER)
pathway.
As
target-based
drug
therapy
for
cancer,
inhibition
PARP
stops
PARP-1
-2
from
damaged
mutated
cancer
cells,
eventually,
cells
die.
Considering
limited
available
therapies
treatment
advanced
recurrent
cancers,
inhibitors
(PARPi)
first
approved
drugs
particularly
target
response
to
BRCA
(BReast
CAncer
gene)-1/2
ovarian,
pancreatic,
prostate,
breast
cancers.
Recently,
six
PARPi
viz.,
olaparib,
rucaparib,
niraparib,
talazoparib,
fuzuloparib,
pamiparib
were
monotherapy
or
combination
with
other
classes
anticancer
agents
maintenance
Moreover,
appears
improve
progression-free
survival
women
platinum-sensitive
ovarian
an
adjuvant
conventional
treatment.
Importantly,
use
management
germline
BRCA1/2-associated
is
novel
therapeutic
strategy,
representing
successful
targeted
improving
outcomes
patients
hereditary
Although
resistance
these
has
been
reported
recently,
however,
strategies
have
employed
overcome
sensitivity
breast,
gastric,
prostate
Mass Spectrometry Reviews,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 23, 2025
ABSTRACT
Cancer
is
the
leading
cause
of
death
worldwide
characterized
by
patient
heterogeneity
and
complex
tumor
microenvironment.
While
genomics‐based
testing
has
transformed
modern
medicine,
challenge
diverse
clinical
outcomes
highlights
unmet
needs
for
precision
oncology.
As
functional
molecules
regulating
cellular
processes,
proteins
hold
great
promise
as
biomarkers
drug
targets.
Mass
spectrometry
(MS)‐based
proteomics
illuminated
molecular
features
cancers
facilitated
discovery
or
therapeutic
targets,
paving
way
innovative
strategies
that
enhance
personalized
treatment.
In
this
article,
we
introduced
tools
current
achievements
MS‐based
proteomics,
choice
targeted
MS
from
to
validation
phases,
profiling
sensitivity
bulk
samples
single‐cell
level
tissue
liquid
biopsy
specimens,
regulatory
landscape
protein
laboratory‐developed
tests
(LDTs).
The
challenges,
success
future
perspectives
in
translating
research
assay
into
applications
are
also
discussed.
With
well‐designed
studies
demonstrate
benefits
meet
requirements
both
analytical
performance,
assays
promising
with
numerous
opportunities
improve
cancer
diagnosis,
treatment,
monitoring.
Biomedicines,
Год журнала:
2025,
Номер
13(2), С. 483 - 483
Опубликована: Фев. 15, 2025
Background:
High-grade
advanced
ovarian,
fallopian
tube,
and
primary
peritoneal
(HGAOC)
cancers
require
both
surgical
systemic
treatment.
The
introduction
of
polyADP-ribose
polymerase
inhibitors
(PARPis)
has
significantly
improved
outcomes.
This
study
presents
an
analysis
HGAOC
patients
treated
at
a
single
center,
following
updated
guidelines.
Methods:
We
observed
437
women
newly
diagnosed
with
the
Department
Gynecological
Oncology
between
January
2018
December
2023.
Results:
Since
November
2022,
first-line
treatment
included
bevacizumab
PARPi,
regardless
residual
disease
post-cytoreductive
surgery.
In
BRCA1/2-mutated
non-mutated
groups,
PARPi-based
regimens
increased
after
May
2021
(p
<
0.01).
Recurrence
number
emerged
as
strong
prognostic
factor
for
survival
0.001),
each
recurrence
raising
mortality
risk
by
80%.
Median
was
21
months
paclitaxel
+
platinum
derivatives
(PC),
27
PC
(BEV),
30
BEV
PARPi.
Conclusions:
rapid
adoption
modern
therapies
our
center
aligned
strategies
HRD
status
global
standards.
However,
variations
in
financial
regulations
drug
accessibility
persist
across
countries.
Despite
these
challenges,
physicians
should
prioritize
most
effective
available.
Letters in Oncology Science,
Год журнала:
2025,
Номер
22(1)
Опубликована: Май 5, 2025
Breast
cancer
is
the
most
common
malignancy
among
women
and
a
leading
cause
of
cancer-related
mortality.
Despite
significant
advances
in
detection
treatment,
its
molecular
heterogeneity
poses
challenges
achieving
accurate
diagnosis
personalized
therapies.
Traditional
diagnostic
methods,
based
primarily
on
histopathology
genomics,
fail
to
capture
full
complexity
disease.
In
response,
multi-omics
approaches,
integrating
transcriptomics,
proteomics,
metabolomics,
are
emerging
as
powerful
tools
for
comprehensive
profiling.
These
advanced
methodologies
enable
identification
novel
biomarkers,
improve
accuracy,
facilitate
patient
stratification
tailored
treatments.
This
review
explores
role
breast
diagnosis,
emphasizing
recent
technological
advancements
key
findings
that
enhance
early
detection,
prognosis,
treatment
strategies.
By
providing
more
complete
picture,
paving
way
precision
medicine,
offering
potential
effective
South African Journal of Bioethics and Law,
Год журнала:
2024,
Номер
unknown, С. e2071 - e2071
Опубликована: Апрель 23, 2024
The
development
of
gene
expression
profiling
and
next-generation
sequencing
technologies
have
steered
oncogenomics
to
the
forefront
precision
medicine.
This
created
a
need
for
harmonious
cooperation
between
clinicians
researchers
increase
access
oncology,
despite
multiple
implementation
challenges
being
encountered.
aim
is
apply
personalised
treatment
strategies
early
in
cancer
management,
targeting
tumour
subtypes
actionable
variants
within
individual’s
broader
clinical
risk
profile
wellbeing.
A
knowledge-generating
database
linked
South
African
Medical
Research
Council’s
Genomic
Centre
has
been
application
medicine,
using
an
integrated
service
research
approach.
Insights
gained
from
patient
experiences
related
heterogeneity,
targeted
therapies
incidental
findings
pathogenic
germline
DNA,
provided
practice-changing
evidence
cost-minimisation
pathology-supported
genetic
testing
strategy.
Integrating
care
with
genomic
through
data
sharing
advances
medicine
maximises
oncology
benefits.
